Cancer is a major global public health issue. Immune checkpoint inhibitors are increasingly used for managing advanced malignancies. However, their effect is limited by immune-related adverse events. Hence, a retrospective, single-institutional study found a 60% clinical benefit ratio among 30 patients receiving Immune checkpoint inhibitors therapy. Nonetheless, a small sample size, patient heterogeneity and retrospective design require further validation for more conclusive results.
Keywords: Non-Small Cell Lung Cancer; efficacy; immunotherapy; nivolumab; real-life.
© 2025 Biomedical Informatics.